Anzeige
Mehr »
Login
Samstag, 25.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Achtung! Ist das die Krypto-Aktie des Jahres 2024 mit 700% Potential?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CVN5 | ISIN: GB00BKPG7Z60 | Ticker-Symbol: 7JN
Frankfurt
24.05.24
08:01 Uhr
0,143 Euro
-0,001
-0,69 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
POOLBEG PHARMA PLC Chart 1 Jahr
5-Tage-Chart
POOLBEG PHARMA PLC 5-Tage-Chart

Aktuelle News zur POOLBEG PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.Poolbeg Pharma PLC Announces Annual Report & AGM Notice104LONDON, UK / ACCESSWIRE / May 9, 2024 / Poolbeg Pharma?(AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative...
► Artikel lesen
09.05.Poolbeg Pharma PLC - Annual Report & AGM Notice-
01.05.Poolbeg Pharma celebrates full patent approval for Immunomodulator II2
01.05.UK's Poolbeg Pharma gains on grant of US patent for immunomodulator drugs1
01.05.Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA160Significant POLB 001 Patent Granted in United StatesImmunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering LONDON, UK / ACCESSWIRE / May 1, 2024 /...
► Artikel lesen
01.05.Poolbeg Pharma PLC - Significant POLB 001 Patent Granted in USA-
30.04.Poolbeg agrees 12-month option over potential Behcet's treatment1
30.04.EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down1
30.04.Poolbeg Pharma announces cash balance of £12.2M as at 31 Dec 20231
30.04.Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023229Significant pipeline advancementsStrategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10BnKey senior management hires LONDON, UK / ACCESSWIRE / April...
► Artikel lesen
30.04.Poolbeg Pharma PLC Announces Appointment of Joint Broker216LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative...
► Artikel lesen
30.04.Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate285Exclusive Option Agreement to Acquire Orphan Drug Candidate for Behçet's DiseaseNovel therapeutic with Fast Track and Orphan DesignationLONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)...
► Artikel lesen
30.04.Poolbeg Pharma PLC - Results for the year ended 31 December 20231
29.04.Poolbeg Pharma PLC Announces TR-1: Notification of Major Holdings123LONDON, UK / ACCESSWIRE / April 29, 2024 / TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format...
► Artikel lesen
20.03.Poolbeg Pharma to be granted US patent1
20.03.Poolbeg Pharma PLC Announces POLB 001 US Patent Update138Notice of Allowance for Significant POLB 001 Patent in United StatesNotice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolioLONDON, UK / ACCESSWIRE / March...
► Artikel lesen
22.02.Poolbeg Pharma PLC Announces Director/PDMR Shareholding191Director Share PurchaseLONDON, UK / ACCESSWIRE / February 22, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and...
► Artikel lesen
19.02.Director dealings: Poolbeg Pharma co-founder ups stake1
19.02.Poolbeg Pharma PLC Announces Director Share Purchase267LONDON, UK / ACCESSWIRE / February 19, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative...
► Artikel lesen
15.02.Poolbeg Pharma announces board role change and launch of EIP1
Seite:  Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1